BioPharmSignal logoBioPharmSignal

Biotech News

Inhibrx Reports First Quarter 2026 Financial Results

Inhibrx (INBX)InhibrxEarnings

Inhibrx Biosciences (INBX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is inhibrx-biosciences.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

NTLAIntellia2026-08-06 11:00 EST

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

IOVAIovance Biotherapeutics, Inc.2026-07-30 12:00 EST

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

NTLAIntellia2026-07-30 12:00 EST

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

IMCRImmunocore Holdings plc2026-08-06 11:00 EST

Immunocore reports second quarter financial results and provides a business update

View all latest news

Inhibrx

Inhibrx is a biotechnology company focused on engineered biologics and oncology, with a strategy that leans into differentiated protein therapeutics. The company’s story is about building value from precise biologic design.

Recent company news

INBXInhibrx2026-07-16 13:00 EST

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

INBXInhibrx2026-06-15 13:15 EST

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

INBXInhibrx2026-05-14 20:02 EST

Inhibrx Reports First Quarter 2026 Financial Results

INBXInhibrx2026-05-11 12:00 EST

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

INBXInhibrx2026-05-08 20:00 EST

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

Stock data

Close
85.79 USD
Market cap
1.37B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States